MammaPrint® is a gene profile test (a genomic test of breast cancer tumour cells) used in patients with early breast cancer, assessed as being at high clinical risk of cancer recurrence, to guide their decision about the use of additional (adjuvant) chemotherapy. After considering safety, clinical effectiveness and cost-effectiveness, The Medical Services Advisory Committee (MSAC) of the Department of Health recently decided not to support public funding for the MammaPrint® test. Your patients may have used or be considering using MammaPrint® and m...